Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -131.60M | -190.60M | -208.80M | -587.00M | -565.30M |
| Total Depreciation and Amortization | 106.30M | 108.80M | 112.40M | 114.00M | 118.40M |
| Total Amortization of Deferred Charges | 2.80M | 7.40M | 10.90M | 23.30M | 27.20M |
| Total Other Non-Cash Items | 65.10M | 44.40M | 39.40M | 309.70M | 466.50M |
| Change in Net Operating Assets | 67.50M | 88.70M | 216.80M | 217.00M | -131.70M |
| Cash from Operations | 110.10M | 58.70M | 170.70M | 77.00M | -84.90M |
| Capital Expenditure | -15.70M | -22.90M | -32.60M | -39.40M | -47.30M |
| Sale of Property, Plant, and Equipment | 46.00M | 7.90M | 7.60M | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 110.20M | 110.20M | 110.20M | 0.00 | 270.20M |
| Other Investing Activities | 55.00M | 30.00M | 0.00 | -6.30M | -6.30M |
| Cash from Investing | 195.50M | 125.20M | 85.20M | -45.70M | 216.60M |
| Total Debt Issued | 234.00M | 284.00M | 304.00M | 85.00M | 70.00M |
| Total Debt Repaid | -473.50M | -482.40M | -498.30M | -128.20M | -563.90M |
| Issuance of Common Stock | 10.90M | 10.80M | 10.70M | 1.40M | 10.20M |
| Repurchase of Common Stock | -1.30M | -1.20M | -1.00M | -800.00K | -800.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.20M | -1.20M | -1.20M | -5.90M | -- |
| Cash from Financing | -231.10M | -190.00M | -185.80M | -48.50M | -484.50M |
| Foreign Exchange rate Adjustments | -700.00K | -- | -1.50M | -400.00K | -1.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 2.60M |
| Net Change in Cash | 73.80M | -6.10M | 68.60M | -17.60M | -351.20M |